Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP624648.RAxfKsw7S1if5HydSF38LUxiYBMxeiJdGIds6qV4jH7FI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP624648.RAxfKsw7S1if5HydSF38LUxiYBMxeiJdGIds6qV4jH7FI130_assertion type Assertion NP624648.RAxfKsw7S1if5HydSF38LUxiYBMxeiJdGIds6qV4jH7FI130_head.
- NP624648.RAxfKsw7S1if5HydSF38LUxiYBMxeiJdGIds6qV4jH7FI130_assertion description "[CtBP2-specific inhibitors, such as MTOB, may be effective adjunct therapies in the management of patients with CtBP2-positive ovarian carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP624648.RAxfKsw7S1if5HydSF38LUxiYBMxeiJdGIds6qV4jH7FI130_provenance.
- NP624648.RAxfKsw7S1if5HydSF38LUxiYBMxeiJdGIds6qV4jH7FI130_assertion evidence source_evidence_literature NP624648.RAxfKsw7S1if5HydSF38LUxiYBMxeiJdGIds6qV4jH7FI130_provenance.
- NP624648.RAxfKsw7S1if5HydSF38LUxiYBMxeiJdGIds6qV4jH7FI130_assertion SIO_000772 23730208 NP624648.RAxfKsw7S1if5HydSF38LUxiYBMxeiJdGIds6qV4jH7FI130_provenance.
- NP624648.RAxfKsw7S1if5HydSF38LUxiYBMxeiJdGIds6qV4jH7FI130_assertion wasDerivedFrom befree-20140225 NP624648.RAxfKsw7S1if5HydSF38LUxiYBMxeiJdGIds6qV4jH7FI130_provenance.
- NP624648.RAxfKsw7S1if5HydSF38LUxiYBMxeiJdGIds6qV4jH7FI130_assertion wasGeneratedBy ECO_0000203 NP624648.RAxfKsw7S1if5HydSF38LUxiYBMxeiJdGIds6qV4jH7FI130_provenance.